(RTTNews) - AstraZeneca plc (AZN.L, AZN) announced positive top-line results from the Phase III AMPLIFY trial for Duaklir (aclidinium bromide/formoterol 400µg/12µg twice-daily), which met its primary ...
Hello and welcome back to Equity, a podcast about the business of startups, where we unpack the numbers and nuance behind the headlines. This is our Wednesday show, where we niche down to a single ...
“Positive” results from the AMPLIFY Phase III trial showed AstraZeneca’s (AZN) Calquence in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback